Published in Mol Ther Oncolytics on November 16, 2016
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Tumor angiogenesis. N Engl J Med (2008) 11.30
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene (2005) 5.58
The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol (2009) 5.44
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Determinants of translation efficiency and accuracy. Mol Syst Biol (2011) 2.24
Nanoparticles for drug delivery in cancer treatment. Urol Oncol (2008) 2.21
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol (2015) 2.11
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther (2005) 2.04
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2010) 2.01
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev (2015) 1.53
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47
The regulation of mRNA stability in mammalian cells: 2.0. Gene (2012) 1.46
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
CAR T cells for solid tumors: armed and ready to go? Cancer J (2014) 1.29
Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol (2015) 1.18
Targeted drug delivery in cancer therapy. Technol Cancer Res Treat (2005) 1.13
Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun (2010) 1.11
Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol (2005) 1.01
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol (2011) 0.99
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother (2012) 0.98
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol (2013) 0.98
The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 0.93
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol (2012) 0.92
Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res (1994) 0.92
Vascular endothelial growth factor receptors: expression and function in solid tumors. Clin Adv Hematol Oncol (2004) 0.92
Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. Annu Rev Pharmacol Toxicol (2016) 0.90
Temperature fluctuations during deep temperature cryopreservation reduce PBMC recovery, viability and T-cell function. Cryobiology (2013) 0.88
Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother (2013) 0.87
A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother (2014) 0.87
Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. Blood (2013) 0.85
Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Curr Gene Ther (2014) 0.83
Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther (2015) 0.82
Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Anticancer Res (2012) 0.81
Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2. Biochem Biophys Res Commun (2010) 0.77
Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer Gene Ther (2012) 0.76
Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy. Biochem Biophys Res Commun (2016) 0.76